FDA orders clinical hold on Targeted Genetics trial

The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis.

James G. Dickinson

September 1, 2007

4:00 am

The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

From the September 01, 2007 Issue of MM+M - Medical Marketing and Media

From Our Partners

Prioritizing audience quality and contextual environment in POC marketing

Partner Content

Prioritizing audience quality and contextual environment in POC marketing

Despite the growing popularity of POC marketing via EHR platforms, this channel remains highly fragmented. For omnichannel marketers, that fragmentation can represent challenges in finding scale, transparency, and uniformity in targeting and performance reporting.

Want to better engage patients with complex diagnoses? Embrace digital.

Partner Content

Want to better engage patients with complex diagnoses? Embrace digital.

Patients often struggle to find specialist care, delaying needed treatment. Digital tools can help.

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.